Home »

MolMed Signs an Agreement With GlaxoSmithKline to Develop a Production Process for a Gene Therapy

MILAN, ITALY — (Marketwire) — 08/05/11 — MolMed S.p.A. (MILAN: MLM) today announced that it has signed an agreement with GlaxoSmithKline (GSK) under which MolMed will develop a production process for an investigational gene therapy for ADA-SCID (Adenosine Deaminase Deficiency – Severe Combined Immune Deficiency), a very rare and life-threatening disease that affects approximately 350 children worldwide. Under the terms of the agreement, MolMed will receive up to EUR 5.5 million in revenues o

Analytics

© 2020 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de